← Back to Search

Behavioural Intervention

Golf Exercise for Prostate Cancer Survivors (GREENS Trial)

N/A

Recruiting

Led By George Salem, PhD

Research Sponsored by University of Southern California

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

First time, primary diagnosis of prostate cancer (PCa)

Currently receiving androgen deprivation therapy (ADT) and/or androgen receptor blocker for more than 6 months

Must not have

Symptomatic cardiovascular disease, active angina, uncontrolled hypertension (systolic blood pressure (SBP) > 160 or diastolic blood pressure (DBP) > 90, high resting pulse heart rate (HR) > 90), symptomatic orthostatic hypotension

Unstable asthma, exacerbated chronic obstructive pulmonary disease (COPD)

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 3 years

Awards & highlights

No Placebo-Only Group

Summary

This trial aims to study how participating in a golf exercise program can help prostate cancer survivors. Golf involves using various muscle groups, walking on uneven terrain, and maintaining balance, which can benefit physical and mental

Who is the study for?

This trial is for underrepresented prostate cancer survivors who can participate in physical activities. It's designed to help improve their quality of life, functional abilities, and psychosocial health after treatment. Specific eligibility criteria are not provided.

What is being tested?

The study tests a golf recreational exercise program tailored for prostate cancer survivors. It involves various activities like walking on uneven terrain, balance tasks, and using all muscle groups during the golf swing to see if it benefits survivorship.

What are the potential side effects?

Since this intervention involves physical activity through golfing, potential side effects may include muscle soreness or strain, fatigue from exercise, joint pain due to movement on uneven surfaces, and possible injury from sports-related accidents.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have been diagnosed with prostate cancer for the first time.

Select...

I have been on hormone therapy for prostate cancer for over 6 months.

Select...

I can stand on my own without help.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I do not have uncontrolled high blood pressure, heart disease symptoms, or very fast heart rates.

Select...

My asthma or COPD is not under control.

Select...

I have been diagnosed with a second cancer or have cancer that has spread to my bones.

Select...

I have a movement disorder or partial paralysis.

Select...

I have severe problems with my vision or hearing.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 3 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 3 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 3 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Balance Confidence

Circulating inflammatory biomarker levels

Cognitive function

+10 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: Supportive care (golf program)Experimental Treatment9 Interventions

Patients participate in the golf training program composed of group sessions over 1-2 hours with a PGA professional two times per week for ten weeks. Training consists of complimentary/warm up exercises integrated with pelvic floor muscle training, golf instruction, golf practice, and golf play on a Par 3 public golf course. Patients also wear an activity tracker and undergo blood sample collection on the study.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Physical Examination

2019

Completed Phase 1

~1200

Biospecimen Collection

2004

Completed Phase 3

~2020